Safety and efficacy of telbivudine for the treatment of chronic hepatitis B.

Grade 3/4 elevations in CPK were also seen with more frequency in the telbivudine group in study 015 (8.4% versus 3.0% in the lamivudine group) but this did not reach statistical significance ( P = 0.06). 15 The only other serious adverse event not related to muscle enzymes or myopathy associated with telbivudine was one instance of liver failure which occurred with an episode of virologic breakthrough that occurred with the development of telbivudine resistance in the GLOBE trial. 19 Post-marketing reports have added additional case reports of myopathy and CPK elevations to the literature, 28 , 29 as well as case reports of neuralgia and numbness and cardiac arrhythmia. 29 The mechanisms for myopathy and peripheral neuropathy are not clear.

also in 111,027 other papers